This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
home:diseases:celiac [07.19.2019] – [Epidemiology] sallieq | home:diseases:celiac [04.26.2020] – [recent research] sallieq | ||
---|---|---|---|
Line 68: | Line 68: | ||
Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
- | In 2015 I read that 6 individuals in the USA are currently | + | In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. |
+ | |||
+ | Gluten in " | ||
2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | ||
(({{pubmed> | (({{pubmed> | ||
+ | |||
+ | Research associated with J Tye-Din | ||
+ | |||
+ | |||
{{tag> | {{tag> |